Physicist measures Radiance 330 proton beam characteristics
January 22, 2014 — Physicists at the McLaren Proton Therapy Center (MPTC) in Flint, Michigan conducted clinical testing of ProTom International, Inc.’s Radiance 330 Proton Therapy System.
Radiance 330 employs the Proton Beam Scanning (PBS) treatment delivery technique, and the McLaren team tested key characteristics of the scanned beam delivered to instrumentation in water phantoms.
“We have been impressed by the stability of the system during our testing,” said Sung Park, Ph.D., chief physicist at MPTC. “The spot size and spot profiles are well-described by a Gaussian distribution and demonstrate excellent radial symmetry. This bodes well for the dosimetry we can expect from ProTom's system.”
The U.S. Food and Drug Administration (FDA) has not yet cleared Radiance 330 Proton Therapy System for commercial distribution in the United States.
For more information: www.protominternational.com, www.mclaren.org
May 14, 2024 
